Aardvark Therapeutics (AARD) Other Accumulated Expenses (2024 - 2026)

Aardvark Therapeutics has reported Other Accumulated Expenses for 3 years, with the latest figure at $755000.0 in Q1 2026.

• Quarterly Other Accumulated Expenses rose 18.9% year-over-year to $755000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $755000.0 (up 18.9% YoY) and the FY2025 annual result came in at $422000.0, up 143.93% from the prior year.
• Other Accumulated Expenses advanced to $755000.0 in Q1 2026 per AARD's latest filing, from $422000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $755000.0 in Q1 2026 and troughed at $173000.0 in Q4 2024.
• A 3-year average of $435333.3 and a median of $371000.0 in 2025 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2025 and 2026: Other Accumulated Expenses soared 143.93% in 2025, then rose 18.9% in 2026.
• Over 3 years, Other Accumulated Expenses stood at $173000.0 in 2024, then jumped by 143.93% to $422000.0 in 2025, then soared by 78.91% to $755000.0 in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $755000.0, $422000.0, and $320000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.